论文部分内容阅读
目的:探讨CD13在宫颈癌患者中的表达及临床意义。方法:用免疫组化SP法检测60例宫颈癌、60例宫颈上皮内瘤变(CIN)和30例正常宫颈组织中的CD13表达情况。结果:CD13在宫颈癌、CIN和正常宫颈组织中的阳性表达率分别是81.7%、31.7%、20.0%,CD13在宫颈癌中的表达均显著高于CIN及正常组织(P均<0.05)。CD13表达与宫颈癌患者年龄无相关性(P>0.05),而与淋巴转移、临床分期以及分化程度有相关性(P<0.05)。结论:CD13在宫颈癌的异常表达与宫颈癌的发生、发展有关,可作为评估宫颈癌的恶性程度、指导治疗、评价预后的重要参考指标。
Objective: To investigate the expression and clinical significance of CD13 in cervical cancer patients. Methods: The expressions of CD13 in 60 cases of cervical cancer, 60 cases of cervical intraepithelial neoplasia (CIN) and 30 cases of normal cervical tissue were detected by immunohistochemical SP method. Results: The positive rates of CD13 in cervical cancer, CIN and normal cervical tissues were 81.7%, 31.7%, 20.0% respectively. The expression of CD13 in cervical cancer was significantly higher than that in CIN and normal tissues (all P <0.05). There was no correlation between the expression of CD13 and the age of cervical cancer (P> 0.05), but correlated with lymphatic metastasis, clinical stage and degree of differentiation (P <0.05). Conclusion: The abnormal expression of CD13 in cervical cancer is related to the occurrence and development of cervical cancer, which can be used as an important reference index for assessing the malignant degree, guiding treatment and prognosis of cervical cancer.